She-Juan An
Overview
Explore the profile of She-Juan An including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
1084
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Yang X, Huang L, Chen Y, An S, Zhang X, Liao R, et al.
Chin J Cancer Res
. 2015 Jul;
27(3):301-8.
PMID: 26157327
Background: Available study revealed advanced tumors have a higher expression rate of MAGE-A3 gene which has a lot of single nucleotide polymorphism (SNP) loci with polymorphisms. This study aimed to...
12.
Machiela M, Hsiung C, Shu X, Seow W, Wang Z, Matsuo K, et al.
Int J Cancer
. 2014 Dec;
137(2):311-9.
PMID: 25516442
Recent evidence from several relatively small nested case-control studies in prospective cohorts shows an association between longer telomere length measured phenotypically in peripheral white blood cell (WBC) DNA and increased...
13.
Yang L, Zhang X, Yang X, Yang J, Wang Z, Chen H, et al.
Oncologist
. 2014 Sep;
19(10):1084-90.
PMID: 25223463
Background: Substantial progress has been made in the treatment of malignancies in the People's Republic of China in recent years. The goal of this study was to identify the extent...
14.
Su J, Zhang X, An S, Zhong W, Huang Y, Chen S, et al.
Chin J Cancer
. 2014 May;
33(7):346-50.
PMID: 24823994
As molecular targets continue to be identified and more targeted inhibitors are developed for personalized treatment of non-small cell lung cancer (NSCLC), multigene mutation determination will be needed for routine...
15.
Huang L, An S, Chen Z, Su J, Yan H, Wu Y
J Thorac Oncol
. 2014 Apr;
9(5):725-8.
PMID: 24722158
Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and Met inhibitors have enabled progress in the management of advanced non-small-cell lung cancer (NSCLC). However, the clinical benefits of these...
16.
Bai X, Lin J, Zhang X, Xie Z, Yan H, Chen Z, et al.
Cancer Biomark
. 2013 Jun;
13(1):37-47.
PMID: 23736020
Background: The hedgehog (Hh) pathway is involved in embryogenesis and organogenesis. GLI3 is one of the zinc-finger transcription factors in the Hh signaling pathway, which exist in both full-length (GLI3FL)...
17.
Guan J, Zhong W, An S, Yang J, Su J, Chen Z, et al.
Ann Surg Oncol
. 2012 Dec;
20(4):1381-8.
PMID: 23208128
Background: The prognostic and predictive value of KRAS mutations in patients with lung cancer is controversial. Biases in disease stage, treatment regimen, small-scale patient studies, and biomarker status have led...
18.
Lan Q, Hsiung C, Matsuo K, Hong Y, Seow A, Wang Z, et al.
Nat Genet
. 2012 Nov;
44(12):1330-5.
PMID: 23143601
To identify common genetic variants that contribute to lung cancer susceptibility, we conducted a multistage genome-wide association study of lung cancer in Asian women who never smoked. We scanned 5,510...
19.
An S, Lin Q, Chen Z, Su J, Cheng H, Xie Z, et al.
Exp Ther Med
. 2012 Nov;
4(2):226-230.
PMID: 23139712
Laminin 5 (Ln5) is an extracellular matrix protein that plays an important role in cell migration and tumor invasion. This study explored the expression of Ln5 and the role of...
20.
An S, Chen Z, Su J, Zhang X, Zhong W, Yang J, et al.
PLoS One
. 2012 Jul;
7(6):e40109.
PMID: 22768234
Background: Appropriate patient selection is needed for targeted therapies that are efficacious only in patients with specific genetic alterations. We aimed to define subgroups of patients with candidate driver genes...